Clinical trials: Tick-Borne Infections
- Condition Tick-Borne Infections
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers…
- Trial name
- NCT00161876
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Poland
- Volunteers
- 3,973 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
The objective of this study is to assess the TBE antibody persistence approximately three years after administration of a TBE booster vaccination with FSME-IMMUN 0.25 ml Junior in children who received either 0.25 mL or 0.5 mL…
- Trial name
- NCT00163618
- Testing
- Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
- Where
- 4 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Tick Borne Encephalitis (TBE)
An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE
This study will evaluate the durability of antibody responses in children and adolescents after primary immunization with TBE vaccine
- Trial name
- NCT01106482
- Testing
- Serology blood draw
- Where
- 10 sites in Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Encephalitis, Tick-borne
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
The objective of this study is to investigate the immunogenicity and safety of a third vaccination with FSME-IMMUN 0.5 ml given approximately 12 months after the second vaccination in Study 225.
- Trial name
- NCT00163540
- Testing
- Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or…
- Trial name
- NCT00840801
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
The purpose of this study is to investigate the safety of five consecutive lots of FSME-IMMUN NEW in healthy volunteers. The main criterion for investigation is the fever rate after the first vaccination in three different age…
- Trial name
- NCT00161863
- Testing
- FSME-IMMUN NEW 0.25 ml
- Where
- 8 sites in Austria, Germany and 1 more
- Sponsor
- Pfizer
Lyme Disease
Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
This study is to understand if the study vaccine (called VLA15) is safe in healthy children. We are looking for children who: are healthy are age 5 through 17 have not been diagnosed with any form of Lyme disease in the past have…
- Trial name
- NCT05634811
- Testing
- VLA15, Normal Saline
- Where
- 65 sites in United States
- Volunteers
- 3,547 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease, Healthy
Lyme Disease Diagnostic Assay - Collection of Whole Blood
The primary objective is to obtain whole blood from subjects with signs and/or symptoms of early Borrelisois. Whole blood will also be obtained from subjects with suspicion of acute Borreliosis and under medical examination for…
- Trial name
- NCT05041595
- Testing
- Lyme diagnostic assay
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- DiaSorin Inc.
Encephalitis, Tick-borne
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations…
- Trial name
- NCT00161954
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe.
- Trial name
- VALOR (NCT05477524)
- Testing
- VLA15, Saline
- Where
- 129 sites in United States, Canada and 5 more
- Volunteers
- 12,546 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease
Lyme Test Indication Combinations (LyTIC) Study
To establish performance of individual tests and combinations of tests (serological, molecular and cellular tests) in early Lyme infection diagnosis
- Trial name
- LyTIC (NCT03201042)
- Testing
- PCR based assay, Serology based assay, Tcell based assay
- Where
- 60 sites in United States
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Oxford Immunotec
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.
- Trial name
- NCT00161798
- Testing
- Tick-borne encephalitis vaccine
- Where
- 23 sites in Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in…
- Trial name
- NCT00161746
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months after completion of primary immunization…
- Trial name
- NCT00161967
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
blood draw five years after booster-immunization with TBE vaccine to investigate immunogenicity in children
- Trial name
- NCT00452621
- Testing
- blood draw
- Where
- 8 sites in Germany
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Novartis
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three…
- Trial name
- NCT00161889
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 19 sites in Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease
ImmuneSense Lyme Study
ImmuneSense Lyme is a study, which is designed to better understand the immune response to Lyme disease. This is critically important because the immune system may be able to tell us important information about how our own bodies…
- Trial name
- NCT04422314
- Testing
- T-Detect Lyme
- Where
- 34 sites in United States
- Volunteers
- 893 people
- Sponsor
- Adaptive Biotechnologies
Lyme Borreliosis
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules…
- Trial name
- NCT04801420
- Testing
- VLA15
- Where
- 19 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.
- Trial name
- NCT00161772
- Testing
- Tick-borne Encephalitis Vaccine
- Where
- 23 sites in Austria, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer